MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
05. Februar 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
31. Januar 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
20. Dezember 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
15. November 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
01. November 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
31. Oktober 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
16. Oktober 2023 16:00 ET
|
MBX Biosciences, Inc.
MBX 2109 was generally well-tolerated across all dosing cohorts MBX 2109 pharmacokinetics reflected the intended prodrug design and support once-weekly dosing MBX 2109 increased albumin adjusted...
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
09. Oktober 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
03. Oktober 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 03, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
11. September 2023 08:00 ET
|
MBX Biosciences, Inc.
MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium and suppressed endogenous PTH(1-84) CARMEL, Ind., Sept. 11, 2023 (GLOBE NEWSWIRE) -- MBX...